Invitrogen™ IFI35 Polyclonal Antibody

Interferon-Induced Protein 35 (IFI35), encoded by the IFI35 gene, is located on chromosome 17 and is recognized for its role in immune response modulation, especially under viral stress conditions. Structurally, IFI35 is part of a complex regulatory network that influences non-canonical NF-kB signaling. This process involves the proteasomal processing of p105 into the DNA-binding transcription factor p50, which forms a heterodimer with RELB (RELB/p50) to activate cell chemotaxis autonomously. The gene's dynamic expression under viral stress has been linked to various immune regulatory networks and is crucial for immune cell recruitment and maintenance, particularly M2-like tumor-associated macrophages (TAMs) within the tumor microenvironment. IFI35 upregulation is significant in conditions of neuroinflammation and multiple sclerosis, especially in patients treated with interferons (IFN), indicating its potential as a biomolecular marker. Additionally, IFI35's role in triple-negative breast cancer highlights its impact on antitumor immunity, where its ablation enhances the infiltration of effector CD8+ T cells and sensitizes tumors to anti-PD-1 immunotherapy. This positions IFI35 as a key player in both immune response and cancer treatment strategies.